FAO believes that the high international tea price is mainly due to the fact that since 2009, the demand for black tea in the international market has been greater than the supply, and black tea is the main species of global tea production.
According to the report, in 2011, as tea prices rose, the income of tea-exporting countries increased by 2.2% over the previous year, which significantly improved rural incomes in these countries and raised the food safety of households. According to FAO, in 2010, global tea demand increased by 5.6% to 4 million tons.
Reported that the increase in global tea consumption is mainly due to the rapid increase in per capita income of some countries, especially China, India, and other emerging economies. Taking China as an example, in 2009, tea consumption increased by as much as 8.2%. In 2010, it increased by 1.4% to 1.06 million tons, ranking first in the world. Tea consumption in India in 2009 and 2010 increased by 2.4% and 1% respectively, reaching 828,890 tons in 2010.
The FAO Inter-governmental Tea Working Group believes that in recent years, the oversupply situation in the international tea market has gradually improved, supply and demand have become more balanced, and tea prices have also increased over the past 10 years.
Regarding the trend of the international tea market in the next 10 years, the FAO Inter-governmental Tea Working Group believes that global black tea production will maintain an average annual growth of 1.9%, reaching 3.28 million tons by 2021, and the price will remain at 2.75 US dollars per kilogram, slightly lower than The current price level.
At the same time, the growth of global green tea production will be significantly higher than that of black tea. The total output in 2021 will reach 2.6 million tons, of which China's green tea production will reach 2.3 million tons.
Intermediates of Cladribine, Carvedilol, Lurasidone, olmesartan, Risedronate Sodium, Atazanavir, Saxagliptin, Dabigatran,Dapoxetine,Cefixime,Ceftaroline fosamil and etc.
In the short span of time, we have emerged as most promising pharmaceutical intermediates manufacturers, chemical intermediates and bulk drug intermediates suppliers. Our consistent supply, quality products and dedication towards clients have opened up many international avenues for our growth.
In addition, the company also can follow the customer's product needs custom synthesis services
MAIN API PRODUCTS USP/BP
|
PRODUCT NAME |
CAS NUMBER |
SPEVIFICATION |
|
Azithromycin |
117772-70-0 |
BEP |
|
Cefpirome Sulphate sterile |
84957-29-9 |
USP JP16 |
|
Ceftriaxone Sodium (Sterile) |
104376-79-6 |
USP31 |
|
Cefotaxime |
64485-93-4 |
USP30 |
|
Ciprofloxacin HCL |
85721-33-1 |
USP/BP |
|
Gentamicin sulphate |
1405-41-0 |
BP |
|
Levofloxacin |
100986-85-4 |
USP27 |
|
Lincomycin Hydrochloride |
859-18-7 |
EP6.0 |
|
Moxifloxacin Hydrochloride |
186826-86-8 |
USP31 |
|
Tigecycline |
220620-09-7 |
USP |
|
Linezolid |
165800-03-3 |
EP |
|
Dexamethasone |
50-02-2 |
USP/BP/EP |
|
Methylprednisolone |
83-43-2 |
USP/BP/EP |
|
Dexketoprofen trometamol |
156604-79-4 |
BP2008 |
|
Ibuprofen |
15687-27-1 |
BP |
|
Metamizol |
68-89-3 |
DAB |
|
Sulindac |
38194-50-2 |
USP/BP/EP |
|
Naproxcinod |
163133-43-5 |
USP28 |
|
Tripelennamine Hydrochloride |
154-69-8 |
USP28 |
|
Itraconazole |
84625-61-6 |
USP/BP |
|
Cytarabine |
147-94-4 |
USP31 |
|
Leucovorin Calcium |
1492-18-8 |
USP32 |
|
Valsartan |
137862-53-4 |
USP30 |
|
Telmisartan |
144701-48-4 |
USP31 |
|
Rosuvastatin Calcium |
147098-20-2 |
USP/BP |
|
Pitavastatin Calcium |
147526-32-7 |
USP/BP |
|
Fluvastatin |
93957-54-1 |
USP31 |
|
Vinpocetine |
42971-09-5 |
EP6.0 |
|
Atazanavir |
198904-31-3 |
BP |
|
Rosiglitazone |
122320-73-4 |
USP30 |
|
Esomeprazole Magnesium |
161973-10-0 |
USP/BP |
|
Topiramate |
97240-79-4 |
USP31 |
|
Fexofenadine HCl |
153439-40-8 |
Inhouse |
|
Bosentan |
147536-97-8 |
Inhouse |
|
D-Cysteine |
921-01-7 |
Inhouse |
|
D-Phenylalanine |
673-06-3 |
Inhouse |
|
Linagliptin |
668270-12-0 |
Inhouse |
|
Rivaroxaban |
366789-02-8 |
USP |
|
Saxagliptin |
361442-04-8 |
USP |
|
Vildagliptin |
274901-16-5 |
USP |
Major Pharmaceutical Intermediates
| Items Descripation | Structure | Application |
|
MICA ESTER CAS No: 246035-38-1 Purity: ≥98% |
 |
For Cefixime |
|
EHATA CAS No: 64485-82-1 Purity: ≥98% |
 |
For Ceftazidine |
|
2-Chloroadenine CAS No: 1839-18-5 |
 |
For Cladribine, Fludarabine et al |
|
Bicyclo(2,2,1)Heptane-2,3-di-exo-carboximide CAS No: 14805o-29-9 |
 |
For Lurasidne |
|
(R,R)-1,2-Bis(methanesulfonyloxy methyl)Cyclohexane CAS No: 186204-35-3 |
 |
For Lurasidone |
|
3-(Piperazin-1-yl)benzol[d] isothiazole CAS No: 87691-87-0 |
 |
For Lurasidone |
|
Trityl olmesartan CAS No: 144690-92-6 Purity: ≥98% |
|
For olmesartan |
|
3-Acetyl Pyridine CAS No: 350-03-8 |
|
For Risedronate Sodium |
|
3-(AceticAcid)pyridine HCL CAS No: 6419-36-9 |
 |
For Risedronate Sodium |
|
Risedronic Acid CAS No: 105462-24-6 |
 |
For Risedronate Sodium |
|
3-Hydroxy-1-adamantyl-D-Glycine CAS No: 709031-29-8 |
 |
For Saxagliptin |
|
(1s,3s,5s)-3-(aminocarbonyl)-2-azabicyclo(3,1,0) hexane-2-carboxylic acid tert-butyl ester CAS No: 361440-67-7 |
 |
For Saxagliptin |
|
(S)-N-Boc-3- hydroxy-adamantylglycine CAS No: 361442-00-4 |
 |
For Saxagliptin |
|
2-Azabicyclo[3.1.0] hexane-3-carbonitrile, (1s,3s,5s)- CAS No: 866083-42-3 |
 |
For Saxagliptin |
|
Ethyl 3-(pyridin-2-ylamino) propanoate CAS No: 103041-38-9 |
 |
For Dabigatran |
|
N-(4-Cyanophenyl) glycine CAS No: 42288-26-6 |
 |
For Dabigatran |
|
4-methylamino-3-nitrobenzoic Acid CAS No: 41263-74-5 |
 |
For Dabigatran |
|
S-3-Amino-3-phenylpropanoic acid ethyl ester HCL CAS No: 167834-24-4 |
 |
For Dapoxetine |
|
(S)-3-Amino-3-Phemylpropan -1-ol CAS No: 82769-76-4 |
|
For Dapoxetine |
|
(S)-3-Dimethylamino-3-Phemylpropanol CAS No: 82769-75-3 |
|
For Dapoxetine |
|
4-{4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-butynil}-α,α-dimethyl benzene acetic acid CAS No: 832088-68-3 |
For Fexofenadine HCl | |
|
Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate CAS No:154477-54-0 |
|
For Fexofenadine HCl |
|
5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone CAS No 461432-22-4 |
|
For Dapagliflozin |
|
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether CAS No :461432-23-5 |
|
For Dapagliflozin |
Mica Ester,Pharma Intermediates,Ciprofloxacin Hcl Uses,Active Pharmaceutical Ingredients
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.pharma-voice.com